STEVEN TILTON

BRISTOL-MYERS SQUIBB COMPANY · WASHINGTON, DC

Registered · LDAActive

Request introduction →Claim this profile →

At a glance

Works on

Professional highlights appear here once this profile is claimed. Claim it →

Background

Career

BRISTOL-MYERS SQUIBB COMPANY

WASHINGTON, DC · current

The past 12 months

Clients

past 12 months

Filings

past 12 months

Agencies contacted

HOUSE OF REPRESENTATIVESSENATE

Specific issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions

Health Issues · 2026 Q2

Intellectual Property Reform concerning bio-pharmaceutical industry

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade

Trade (domestic/foreign) · 2026 Q2

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act

Medicare/Medicaid · 2026 Q2

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Taxation/Internal Revenue Code · 2026 Q2

Clients

BRISTOL-MYERS SQUIBB COMPANY

2026 · 1 filing

$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings1

2026 Q2

BRISTOL-MYERS SQUIBB COMPANY

Q2lda.gov →